aibioNNNN Anbio Biotechnology
Anbio Biotechnology (NNNN) news
Anbio Biotechnology is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NNNN, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Anbio Biotechnology news
We have not published a story on Anbio Biotechnology yet. When there is news, it will appear here.
Anbio Biotechnology annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $8.6 million | $8.2 million |
| Research and development | $201,305 | $454,227 |
| Net income (loss) | $6.4 million | $2.4 million |
| Cash from operations | -$6.7 million | $2.1 million |
| Cash and equivalents | $7.8 million | $11.8 million |
| Short-term investments | $4.1 million | $0 |
Questions about Anbio Biotechnology
What is the ticker symbol of Anbio Biotechnology?
Anbio Biotechnology trades under the ticker NNNN on NASDAQ.
Where is Anbio Biotechnology listed?
Anbio Biotechnology is listed on NASDAQ.
Which country or territory is Anbio Biotechnology listed under?
Our directory records Anbio Biotechnology under United States.
Does aibio.space cover Anbio Biotechnology?
aibio.space lists Anbio Biotechnology among 2,820 public biotech companies and publishes its news here as stories appear.
What was Anbio Biotechnology's revenue last year?
$8.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Anbio Biotechnology profitable?
Anbio Biotechnology reported net income of $6.4 million for the fiscal year ended Dec 31, 2025, and used $6.7 million of cash in operations, per its annual report to the SEC.
How much does Anbio Biotechnology spend on research and development?
$201,305 in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Anbio Biotechnology have?
$11.9 million in cash and short-term investments at Dec 31, 2025, per its 20-F.
Investor discussion: Anbio Biotechnology
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a reverse stock split. SEC Form 6-K. Source
Stock chart
Listing details
- Company
- Anbio Biotechnology
- Ticker
- NNNN
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction